1 Reason This $900 Stock Could Announce a Split in 2026

Eli Lilly reported fiscal 2025 revenue up 45% YoY to ~$65.2B and EPS up 86% YoY to $24.20, with Mounjaro revenue up 99% to nearly $23B and Zepbound up 175% to ~$13.5B. Management guides fiscal 2026 revenue of $80–$83B, noting pricing headwinds of low- to mid-teens % that volume growth should more than offset. GLP-1 penetration remains mid-single digits in the eligible U.S. obesity population, implying significant upside, and the planned launch of oral GLP-1 orforglipron could broaden the market. Company has committed >$55B to manufacturing expansion since 2020 and is advancing 36 active late-stage (phase 3) programs, supporting durable growth and fueling stock-split speculation.

Analysis

The structural story is not simply demand for an incumbent molecule but a platform shift: once oral GLP-1s and broader delivery options remove the “injection” barrier, adoption curves will be driven by primary-care treatment pathways, payer prior-authorization design, and clinic capacity rather than clinical efficacy alone. That implies the biggest beneficiaries will be players who control scale and distribution (manufacturing footprint, cold-chain/logistics, pen/auto-injector OEMs and ambulatory care providers) because scale converts into both lower unit costs and pricing leverage when PBMs push for formulary consolidation. Conversely, entrants that fragment the market with low-price oral offerings will force a transition from margin-driven growth to volume-driven growth, compressing realized net price per patient over a multi-year window.

Key catalysts are bifurcated by timeframe: safety/regulatory signals or payer policy shifts can move market sentiment in days–weeks, while capacity, guideline updates and real-world durability data will play out over 6–36 months and determine long-run TAM. Manufacturing execution risk is asymmetric — a failure to convert committed capacity into on-market supply would bottleneck growth and spike short-term volatility, whereas successful scale will materially lower marginal costs and open global markets. The largest nonlinear tail-risk is coordinated payer pushback (national step-therapy or severe reimbursement narrowing) which would truncate peak penetration expectations and quickly reprice multiples.

Consensus is pricing in an almost frictionless rollout; it underweights the probability that oral entrants expand patient volume while simultaneously compressing net price and margins. Positioning should therefore be convex to execution (own scale) but protected against policy/safety shocks (option hedges or paired shorts that profit from rapid repricing). Near-term event calendar (manufacturing announcements, guideline statements, large-payer coverage decisions) creates asymmetric option opportunities to monetize elevated implied volatility ahead of clarity.

Key Decisions for Investors

• Core long with downside protection — Establish a 2–4% NAV position in LLY for a 12–24 month horizon and buy a 12-month put at ~20% OTM (size puts to cap drawdown to ~3% of NAV). Rationale: capture secular market expansion while limiting tail loss from regulatory/payer shocks; cost of protection is insurance against binary adverse events.
• Leveraged, limited-risk upside — Buy a Jan 2027 LLY call spread: long 25% OTM, short 60% OTM (size = 1/2 of core position). Pay a modest premium (<10% notional) to get 3–6x upside if penetration and price realization hold, with capped loss if competition compresses prices.
• Volatility harvest around split/speculation — If implied vol spikes into a split/earnings window, sell a near-term (30–60 day) call spread 5–10% OTM funded by the premium, sizing at 25–33% of the core equity position. This expresses a view that the post-split/risk-off pop may be transient; risk is a large upside gap beating the short spread.
• Relative-share pair (execution vs pricing risk) — Pair trade: long LLY (equal notional) vs short NVO for 12–24 months to express confidence in US execution and manufacturing scale while protecting versus global pricing/regulatory divergence. Expect positive carry if LLY out-executes on supply and capture U.S. share; downside if Novo defends via superior outcomes or pricing incentives.